^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Castration-Resistant Prostate Cancer

    Associations
    News

    Trials

    Apply
    Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (NCI-2018-01054) (NCT03360721)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/06/2018
    Primary completion :
    04/30/2027
    Completion :
    04/30/2027
    PTEN
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)
    A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06842498)
    Phase 2
    FibroGen
    Not yet recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/01/2025
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    CD46
    |
    FG-3246
    Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT05730712)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/08/2024
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    NRG1
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) (NCT03748641)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    01/25/2019
    Primary completion :
    10/08/2021
    Completion :
    03/19/2027
    HRD • BRCA
    |
    Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485)
    Phase 1
    Incyte Corporation
    Completed
    Last update posted :
    02/18/2025
    Initiation :
    02/03/2021
    Primary completion :
    01/22/2024
    Completion :
    01/22/2024
    CD8
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (ST101-101) (NCT04478279)
    Phase 1/2
    Sapience Therapeutics
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/01/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF
    |
    HR positive • BRAF mutation
    |
    temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)
    A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) (NCT04709276)
    Phase 2
    Andrew J. Armstrong, MD
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/07/2021
    Primary completion :
    12/01/2025
    Completion :
    06/01/2028
    TP53 • PTEN • RB1 • SYP
    |
    LDH elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel
    Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer (NCT06827080)
    Phase 1/2
    Zhengguo Chen
    Not yet recruiting
    Last update posted :
    02/14/2025
    Initiation :
    02/11/2025
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    FOLH1
    |
    FOLH1 expression
    Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (NCT05219500)
    Phase 2
    Fusion Pharmaceuticals Inc.
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/16/2021
    Primary completion :
    04/30/2025
    Completion :
    07/31/2025
    MSI • BRCA
    |
    BRCA mutation
    |
    FPI-2265
    Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer (COROS) (NCT06783127)
    Phase N/A
    Santa Chiara Hospital
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/01/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    BRCA
    |
    Lynparza (olaparib)
    Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (NCT02769962)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    05/09/2016
    Primary completion :
    07/01/2025
    Completion :
    12/31/2027
    BRCA
    |
    Lynparza (olaparib) • irinotecan
    Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (NCT05457257)
    Phase 4
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/29/2022
    Primary completion :
    10/22/2024
    Completion :
    09/30/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone
    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (C-800-01) (NCT03860272)
    Phase 1
    Agenus Inc.
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/20/2019
    Primary completion :
    01/13/2025
    Completion :
    12/01/2027
    ALK
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    11/22/2021
    Primary completion :
    11/02/2025
    Completion :
    11/02/2025
    CD276 • VTCN1 • CD4 • HHLA2
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (C4391001) (NCT04557449)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/23/2020
    Primary completion :
    09/23/2026
    Completion :
    11/23/2027
    CDKN2A • CCND1 • CD4
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride
    Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers (NCT05588609)
    Phase 2
    Merus N.V.
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/17/2022
    Primary completion :
    10/01/2025
    Completion :
    03/01/2026
    NRG1
    |
    NRG1 fusion
    |
    Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)
    PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    09/24/2018
    Primary completion :
    07/25/2022
    Completion :
    10/03/2025
    HER-2 • ER • PTEN • PIK3CB
    |
    ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    docetaxel • AZD8186
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors (C4551001) (NCT04606446)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/16/2020
    Primary completion :
    08/13/2025
    Completion :
    03/07/2027
    HER-2 • ER • CDKN2A
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)
    Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT04221542)
    Phase 1
    Amgen
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/04/2020
    Primary completion :
    04/15/2026
    Completion :
    08/17/2028
    STEAP1
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • xaluritamig (AMG 509)
    A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (LORIKEET) (NCT05848011)
    Phase 2
    MacroGenics
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    09/28/2023
    Primary completion :
    09/01/2026
    Completion :
    09/01/2027
    BRCA
    |
    BRCA mutation
    |
    docetaxel • prednisone • lorigerlimab (MGD019)
    Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (NCT04631744)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/03/2021
    Primary completion :
    07/01/2026
    Completion :
    07/01/2027
    FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4
    |
    Cabometyx (cabozantinib tablet)
    Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (CHAARTED2) (NCT03419234)
    Phase 2
    ECOG-ACRIN Cancer Research Group
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    04/26/2018
    Primary completion :
    09/30/2025
    Completion :
    04/01/2026
    AR
    |
    AR splice variant 7
    |
    docetaxel • abiraterone acetate • prednisone • cabazitaxel
    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCI-2018-01648) (NCT03682289)
    Phase 2
    Rahul Aggarwal
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    01/17/2019
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    MSI • ATM • ARID1A • UGT1A1
    |
    ATM mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)
    Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC (NCT03093428)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    06/09/2017
    Primary completion :
    04/09/2020
    Completion :
    02/28/2025
    CD4
    |
    Keytruda (pembrolizumab) • Xofigo (radium Ra-223 dichloride)
    Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (PROpelSub) (NCT05171816)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    01/03/2025
    Initiation :
    06/24/2021
    Primary completion :
    01/22/2024
    Completion :
    04/28/2026
    HRD
    |
    BRCA1 mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc (NCT06084338)
    Phase 2
    VA Office of Research and Development
    Recruiting
    Last update posted :
    12/30/2024
    Initiation :
    12/14/2023
    Primary completion :
    11/29/2027
    Completion :
    12/31/2028
    EGFR
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer. (NCT06733337)
    Phase N/A
    Pfizer
    Not yet recruiting
    Last update posted :
    12/13/2024
    Initiation :
    01/31/2025
    Primary completion :
    06/22/2029
    Completion :
    06/22/2029
    BRCA
    |
    Talzenna (talazoparib)
    A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients (NCT01650194)
    Phase 2
    Astellas Pharma Global Development, Inc.
    Completed
    Last update posted :
    12/10/2024
    Initiation :
    07/09/2012
    Primary completion :
    01/04/2018
    Completion :
    01/04/2018
    CYP17A1
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone
    Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects (NCT03248570)
    Phase 2
    University of California, San Francisco
    Completed
    Last update posted :
    11/20/2024
    Initiation :
    02/20/2018
    Primary completion :
    09/28/2023
    Completion :
    09/28/2023
    BRCA1 • BRCA2 • MSI • BRCA
    |
    BRCA1 mutation
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel
    Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB) (NCT05340374)
    Phase 1/2
    Peter MacCallum Cancer Centre, Australia
    Recruiting
    Last update posted :
    11/08/2024
    Initiation :
    07/14/2022
    Primary completion :
    06/20/2026
    Completion :
    12/01/2026
    AR
    |
    docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    Checkpoint Inhibitors and SBRT for MCRPC (CheckPRO) (NCT05655715)
    Phase 2
    Herlev and Gentofte Hospital
    Completed
    Last update posted :
    10/16/2024
    Initiation :
    11/25/2019
    Primary completion :
    08/30/2024
    Completion :
    08/30/2024
    AR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROPEL) (NCT03732820)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    10/08/2024
    Initiation :
    10/31/2018
    Primary completion :
    07/30/2021
    Completion :
    11/04/2024
    HRD
    |
    BRCA1 mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    Pembrolizumab with Combination Chemotherapy in Treating Participants with Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate (NCI-2018-01120) (NCT03582475)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    09/19/2024
    Initiation :
    12/20/2018
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • etoposide IV
    Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy (NCT02099864)
    Phase 2
    OHSU Knight Cancer Institute
    Completed
    Last update posted :
    09/19/2024
    Initiation :
    02/05/2014
    Primary completion :
    10/01/2019
    Completion :
    07/08/2024
    TP53 • PTEN • AR • RB1
    |
    PTEN mutation • AR splice variant 7
    |
    Xtandi (enzalutamide)
    Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY) (NCT05502315)
    Phase 2
    Rana McKay, MD
    Recruiting
    Last update posted :
    07/18/2024
    Initiation :
    02/02/2023
    Primary completion :
    04/12/2026
    Completion :
    04/12/2027
    CD4
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
    Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD) (NCT04704505)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    06/18/2024
    Initiation :
    04/28/2022
    Primary completion :
    02/01/2026
    Completion :
    02/01/2027
    AR
    |
    abiraterone acetate • Xofigo (radium Ra-223 dichloride)
    Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer (NCT05037500)
    Phase 1
    Roswell Park Cancer Institute
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    01/26/2022
    Primary completion :
    01/30/2025
    Completion :
    01/30/2025
    TP53 • RB1
    |
    Xtandi (enzalutamide) • Inqovi (decitabine/cedazuridine)
    Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (NCT05960578)
    Phase 2
    University of Washington
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/06/2024
    Primary completion :
    03/31/2027
    Completion :
    12/31/2027
    TNFA
    |
    apalutamide
    Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer (NCT04592237)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    12/29/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    PD-L1 • TP53 • PTEN • RB1 • CEACAM5
    |
    PTEN mutation
    |
    carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)